The accurate evaluation of cardiovascular disease (CVD) risk in asymptomatic adults is a challenging task. While a basic medical history and standard laboratory tests can provide a rough estimate of risk factor burden, such an estimate is only a rough approximation of risk as many persons suffering CVD events do not necessarily have multiple risk factors, and conversely many who do have multiple risk factors will never suffer a CVD event. In order to best identify asymptomatic persons at risk for future cardiovascular disease (CVD) events, it is important to understand the guidelines for CVD risk assessment and evidence-based methods for evaluation of risk in asymptomatic individuals.

In this review, we will 1) discuss the role and limitations of global risk assessment, 2) review the evidence and recommendations for biomarkers in CVD risk assessment, and 3) review the evidence and recommendations for subclinical disease evaluation / imaging in CVD risk assessment.

Global risk assessment

In 1961, Dr. William B. Kannel, a former director of the Framingham Heart Study, the longest running epidemiologic study of cardiovascular disease which began in 1948, introduced the concept of cardiovascular risk factors from some of the early longitudinal data of the study showing the importance of elevated cholesterol, blood pressure, and smoking in relation to future coronary heart disease (CHD) risk. The concepts of multivariable and global risk assessment, based on estimating risk from the combination of several risk factors (Figure 1) evolved over succeeding decades. Here a direct relation between the number of CHD risk factors present and the cumulative risk of CHD was demonstrated. This further resulted in the development of the Framingham Risk Scores beginning in 1991, as well as other risk scores used in other parts of the world, including the SCORE algorithms in Europe (2-4), which all differ according to the endpoint used, length of follow-up, and risk factors included. The US National Cholesterol Education Program (NCEP) in 2001 recommended the use of global risk assessment scoring specifically for persons at suggested intermediate risk based on the presence of 2 or more risk factors including age>45 years in a male or >55 in a female, hypertension, low HDL-C, current cigarette smoking, and a positive family history of premature CHD, and involving the calculation of 10-year risk of hard CHD defined a nonfatal myocardial infarction or CHD death. However, measures of obesity, physical inactivity, or family history were not included in the Framingham risk algorithms and the NCEP 2001 algorithm designated diabetes a CHD risk equivalent, so this was not included as well. For example, one can apply different risk scoring systems to a given case study, a 67-year old woman, non-smoker, with total cholesterol of 210 mg/dl, systolic blood pressure of 138 mmHg, and HDL-cholesterol of 42 mg/dl. She also has a triglyceride level of 201 mg/dl, waist circumference of 36 inches, and fasting glucose of 109 mg/dl which do not factor into these risk scores, but show that she has all five metabolic syndrome risk factors. Depending on what risk score is used, one gets dramatically different results, ranging from only 1-2% of the European SCORE algorithm for fatal CVD is used, to 3% if the 10-year hard CHD Framingham risk score is used (6), 10% if the Framingham 10-year total CVD risk score is used, to 39% if lifetime risk is estimated. While many physicians might suggest she is at high risk on the basis of having all five metabolic syndrome risk factors, the wide estimates in risk obtained demonstrate that the degree and severity of risk factors plays an important role in risk estimation as does the endpoint (CHD vs. CVD) and duration (10-year vs. 30-year or lifetime) of risk of interest.

Many persons who suffer CVD events are not at high risk; in fact, 56% or 87 million persons in the US have low short-term but high lifetime risk and lifetime risk for total CVD is approximately 60% in men and 50% in women.
Global risk scoring algorithms are therefore only moderate accurate for identifying those who will eventually suffer a major coronary event. There are a number of criteria that are required for a good screening test for evaluation of CVD risk. These criteria include sensitivity in identifying those who have a condition of interest, providing reproducible results, detecting those where early intervention is likely to have a beneficial impact, and being able to provide incremental value to risk predicted by office-based risk assessment (e.g., risk scores). While multivariable regression analyses can identify whether a particular new measure predicts outcomes independently of standard risk factors and/or other measures, the performance of a new test against or in addition to a standard set of risk factors or global risk score (e.g., office-based risk assessment) can be better examined by comparing the C-statistic obtained from receiver operator curve (ROC) analyses. While this test has often been criticized for being overly conservative, it does provide the ability to statistically compare models with or without the addition of a new test of interest. Standard risk factors alone or a global risk score will often provide a C-statistic in the range of 0.65-0.70 and most biomarkers or screening tests will increase this modestly to 0.70-0.80, with statistical significance depending on the degree of increase in C-statistic and sample size.

A screening test can be applied to those initially at intermediate (e.g., 10-20%) risk and if positive, would stratify that person to a higher risk category, and if negative would stratify them to a lower risk category (Figure 2). A new metric for clinical utility, the net reclassification index, is defined as the net proportion of persons who are correctly reclassified from the new test, or the sum of 1) cases whose risk is stratified upward (correct) by the test being positive minus the cases where risk is stratified downward (incorrect) and 2) controls whose risk is stratified downward (correct) minus those who are stratified upward (incorrect). This measure requires a clear definition of cutpoints for defining boundaries for low, intermediate, and high risk and positivity of a test.

In 2010, the American College of Cardiology Foundation (ACCF) / American Heart Association (AHA) guidelines for CVD risk assessment in asymptomatic adults were published and forms the basis for the recommendations and screening tests discussed in this report. They graded a large number of screening tests according to the

---

**Criteria for assessing the performance of newer screening tests**

Global risk scoring algorithms are therefore only moderate accurate for identifying those who will eventually suffer a major coronary event. There are a number of criteria that are required for a good screening test for evaluation of CVD risk. These criteria include sensitivity in identifying those who have a condition of interest, providing reproducible results, detecting those where early intervention is likely to have a beneficial impact, and being able to provide incremental value to risk predicted by office-based risk assessment (e.g., risk scores). While multivariable regression analyses can identify whether a particular new measure predicts outcomes independently of standard risk factors and/or other measures, the performance of a new test against or in addition to a standard set of risk factors or global risk score (e.g., office-based risk assessment) can be better examined by comparing the C-statistic obtained from receiver operator curve (ROC) analyses. While this test has often been criticized for being overly conservative, it does provide the ability to statistically compare models with or without the addition of a new test of interest. Standard risk factors alone or a global risk score will often provide a C-statistic in the range of 0.65-0.70 and most biomarkers or screening tests will increase this modestly to 0.70-0.80, with statistical significance depending on the degree of increase in C-statistic and sample size.

A screening test can be applied to those initially at intermediate (e.g., 10-20%) risk and if positive, would stratify that person to a higher risk category, and if negative would stratify them to a lower risk category (Figure 2). A new metric for clinical utility, the net reclassification index, is defined as the net proportion of persons who are correctly reclassified from the new test, or the sum of 1) cases whose risk is stratified upward (correct) by the test being positive minus the cases where risk is stratified downward (incorrect) and 2) controls whose risk is stratified downward (correct) minus those who are stratified upward (incorrect). This measure requires a clear definition of cutpoints for defining boundaries for low, intermediate, and high risk and positivity of a test.

In 2010, the American College of Cardiology Foundation (ACCF) / American Heart Association (AHA) guidelines for CVD risk assessment in asymptomatic adults were published and forms the basis for the recommendations and screening tests discussed in this report. They graded a large number of screening tests according to the
Table 1. Recommendations for cardiovascular risk assessment in asymptomatic adults, adapted from Greenland et al. 2

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Recommendation</th>
<th>AHA/ACC Classification of Recommendation and Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Risk Scoring</td>
<td>Should be obtained in all asymptomatic adults without a clinical history of CHD</td>
<td>I-B</td>
</tr>
<tr>
<td>Family History</td>
<td>Should be obtained for cardiovascular risk assessment in all asymptomatic adults</td>
<td>I-B</td>
</tr>
<tr>
<td>Genomic Testing</td>
<td>Genotype testing for CHD risk assessment is not recommended for asymptomatic adults</td>
<td>III-B</td>
</tr>
<tr>
<td>Lipoprotein and Apolipoprotein Assessments</td>
<td>Measurement of lipid parameters, including lipoproteins, apolipoproteins, particle size, and density, beyond a standard fasting lipid profile is not recommended for cardiovascular risk assessment</td>
<td>III-C</td>
</tr>
<tr>
<td>Natriuretic Peptides</td>
<td>Measurement not recommended for CHD risk assessment in asymptomatic adults</td>
<td>III-B</td>
</tr>
<tr>
<td>C-reactive Protein</td>
<td>Men aged 50 and over or women aged 60 and over with LDL-C&lt;130 mg/dl without CHD or inflammatory conditions</td>
<td>IIa-A</td>
</tr>
<tr>
<td></td>
<td>Asymptomatic intermediate risk men &lt;=50 years or women &lt;=60 years. Not recommended for high risk adults or those at low risk &lt;50 years in men or &lt;60 years in women.</td>
<td>IIb-B</td>
</tr>
<tr>
<td>Hemoglobin A1c</td>
<td>Measurement reasonable for cardiovascular risk assessment in asymptomatic adults with or without diabetes</td>
<td>IIb-B</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>Measurement reasonable for cardiovascular risk assessment in asymptomatic adults with hypertension or diabetes</td>
<td>IIa-B</td>
</tr>
<tr>
<td></td>
<td>Measurement reasonable in those at intermediate risk without hypertension or diabetes</td>
<td>IIb-B</td>
</tr>
<tr>
<td>Lipoprotein-Associated Phospholipase A2</td>
<td>Measurement reasonable for cardiovascular risk assessment in intermediate-risk asymptomatic adults</td>
<td>IIb-B</td>
</tr>
<tr>
<td>Resting Electrocardiogram</td>
<td>Reasonable for risk assessment in asymptomatic adults with hypertension or diabetes</td>
<td>IIa-C</td>
</tr>
<tr>
<td></td>
<td>May be considered for cardiovascular risk assessment in asymptomatic adults without hypertension or diabetes</td>
<td>IIb-C</td>
</tr>
</tbody>
</table>

strength of recommendation or size of effect (Class I being strongest indicating the test or intervention should be performed, Class IIa where it is reasonable to perform the test or intervention, IIb where the test or intervention may be considered, to Class III being weakest indicating the test or intervention should not be performed) and level of evidence (A being strongest and C being weakest) (Figure 3). Table 1 shows a summary of the recommendations for different risk assessment strategies ranging from global risk scoring to biomarkers to subclinical CVD assessment, with several key modalities discussed below.

**Inflammatory factors and other biomarkers**

The potential role of inflammatory and other biomarkers for the prediction of initial and recurrent CVD events has been an active area of investigation for nearly two decades. Much of this interest was prompted initially by the numerous prospective studies documenting high sensitivity C-reactive protein to be an independent risk factor for CVD events with approximately a two to four-fold greater risk associated with being in the highest vs. lowest quartile11. These studies, as well as the JUPITER clinical trial involving rosuvastatin given to persons with normal LDL-C but elevated hs-CRP resulting in significant CVD event reduction, have led to the hs-CRP recommendations from the ACCF/AHA statement and the National Lipid Association expert panel. They do recommend (Class IIa or IIb, level of evidence B) hs-CRP assessment in men aged 50 years or over or women aged 60 years and over not on lipid-lowering therapy but with an LDL-C<130 mg/dl, as well as younger intermediate risk persons. Measurement, however, is not recommended in higher or lower risk persons2. Moreover, while some studies do show hs-CRP to provide incremental clinical utility for risk assessment over risk factors, this is not a universal finding and adoption of routine testing of hs-CRP by clinicians still remains limited. A finding of an elevated hs-CRP level has been best utilized to provide the impetus for starting preventive therapies, particularly statins, when patient risk and LDL-C levels are insufficient to otherwise provide a convincing case for such therapy.

Elevated levels of lipoprotein associated phospholipase A2 (LpPla2) are also shown from a large meta-analysis to confer excess risk of CVD events, and to provide
additive value in combination with hs-CRP for identification of higher risk persons\(^2\). The guideline panels did give LpPla\(_2\) a class IIb level of evidence B recommendation for measurement in those at intermediate risk\(^2\).

B-type natriuretic peptides (BNP) have also been shown to be positively associated with CVD risk both in persons with and without existing CVD from large meta-analyses\(^3\), with an overall hazard ratio (HR) of 2.8 comparing those in the highest vs. lowest tertile; however, there are only very modest improvements in discrimination as measured by the C-statistic have been noted, and the ACCF/AHA panel did not recommend (Class III) its measurement for CHD risk assessment in asymptomatic adults\(^2\).

It is possible that a multimarker approach utilizing biomarkers representing complementary, but different pathologies may be practical in the future and numerous groups are trying to identify the “cocktail” of biomarkers that will serve to significantly enhance risk reclassification. For example, such a combination of biomarkers might involve inflammation, myocyte necrosis, hemodynamic stress, accelerated atherosclerosis, and vascular damage. An example from the Framingham Heart Study utilizing five distinct biomarkers (BNP, C-reactive protein, urine albumin/creatinine, homocysteine, and renin) shows an index consisting of the biomarkers to be independently associated with risk of CVD events; however, only a very modest improvement in C-statistic was observed\(^4\). Some other prospective studies, such as in older adults documented a significant improvement in C-statistic from adding troponin, NT-pro BNP, cystatin C, and C-reactive protein to risk factors (C-statistic improvement from 0.67 to 0.77, \(p<0.001\))\(^1\)\(^5\), as well as the Belfast PRIME cohort showing troponin, NT-pro BNP, and C-reactive protein together to significantly improve discrimination for predicting events (C-statistic improvement from 0.67 to 0.70, \(p<0.001\))\(^1\)\(^6\).

While somewhat obvious, but poorly documented in the medical history, a premature family history of CHD is strongly associated with future risk and a careful evaluation of family history in all first degree relatives is recommended (I-B); however, genomic screening, despite its popularity, has not been proven to provide incremental predictive utility for CVD events over standard risk assessment and is not recommended (III-C). Modest recommendations, however, are made for the assessment of HbA1c in persons without diabetes (IIa-B), as well as urinary albumin excretion, especially in those with hypertension or diabetes (IIb-B)\(^2\).
Subclinical CVD assessment methods

Screening tools have been developed for evaluating subclinical CVD in just about every part of the body, ranging from carotid ultrasound to aortic and carotid MRI, coronary calcium screening by CT, ankle brachial index for peripheral artery disease, and brachial artery reactivity and radial tonometric techniques for assessing endothelial function (Figure 4). We will review the principal screening modalities (namely carotid ultrasound, ankle-brachial index, and coronary calcification screening) that have the greatest evidence base for cardiovascular risk assessment.

Carotid Ultrasonography. Probably the most established method for examining subclinical atherosclerosis is carotid B-mode ultrasound (Figure 5). It is noninvasive without radiation and of moderate cost and there are numerous clinical trials that have used this as a surrogate endpoint for examining effects of therapeutic interventions such as lipid-lowering on retarding progression of atherosclerosis. Prior studies have shown increased levels of carotid IMT can occur at a relatively early age (e.g., adolescence), thus this technique has the ability to detect at a fairly young age persons who are at potential future risk for CVD events. While the accuracy of assessments of carotid intimal media thicknesses (IMT) depends on the operator, easier more automated devices are being developed which will make its assessment more standardized and applicable to the office-based practitioner. The ACCF/AHA guidelines give IMT measurement a class IIa level of evidence B recommendation in asymptomatic intermediate risk persons. Increased carotid IMT has long been shown to be associated with greater CVD event risk, such as shown by the Cardiovascular Health Study in
the elderly, where among those in the 5th quintile for carotid IMT, one quarter had suffered a MI or stroke within 7 years37. More recently, the Atherosclerosis Risk in Communities study demonstrated the combined importance of both carotid IMT as well as carotid plaques for prediction of CHD events; at each level of carotid IMT, there was added prediction offered by the presence of carotid plaques18. The combination of both was able to reclassify 23% of individuals over traditional risk factors.

**Ankle Brachial Index**. Measurement of subclinical peripheral arterial disease can help identify persons more likely to have vascular disease in other areas as well as increased CVD risk. Ankle brachial index (ABI) measurement involves a simple Doppler tool and is completely noninvasive, with the ratio of the higher of the systolic BP measures from each ankle forming the numerator for the left and right ABI and the higher of the systolic BP measures taken in each arm being the denominator. An ABI <0.9 is diagnostic of peripheral arterial disease. Studies such as the Cardiovascular Health Study have shown the lower the ABI the worse the survival, with <80% of subjects alive after 6 years among those with an ABI <0.919. The more recently reported ABI Collaboration showed that compared to a reference group of 1.1-1.2, those with an ABI <1.0 were at significantly higher risk of total mortality, even those in the borderline 0.9-<1.0 range, there was nearly a two-fold increase in the risk of mortality20. From this study, 19% of men and 38% of women were reclassified in their risk category from the addition of ABI. The test has received a class IIa level of evidence B recommendation for assessment of CVD risk in intermediate risk individuals; the rate for positive tests is quite low, however, until after the age of 60; thus the test is most appropriate for screening older individuals for peripheral arterial disease, which if present, is clearly known to be associated with disease in other vascular beds.

**Coronary Artery Calcium**. Coronary artery calcium (CAC) measured by computed tomography (Figure 6) has established itself as the most potent subclinical disease predictor of future CVD events. Of the subclinical disease measures tested, CAC is unquestionably of greatest predictor of future CVD events. Of the subclinical disease established itself as the most potent subclinical disease (CAC) measured by computed tomography (Figure 6) has events21. While numerous “commercial” scanning cohorts have shown a direct relation between CAC scores and future CHD events, the Multietnic Study of Atherosclerosis (MESA) was the first population-based prospective study to demonstrate this with successively higher rates of CHD events associated with greater CAC scores22. Those with a CAC score >300 compared to 0 had nearly a 7-fold greater risk of major CHD events and 10-fold greater risk of any CHD events. Moreover, incremental discrimination from higher C-statistics were noted in the four major ethnic groups included in MESA over and above standard risk factors. Examination of clinical utility has overall shown 23% of persons with events to be reclassified as high risk and 13% without events reclassified as low risk23. More recently, we demonstrated CAC scoring to stratify risk in those with metabolic syndrome and diabetes; there was a 10-fold or greater gradient in risk of CHD events from those without CAC (0.4% per year) to those with CAC scores of 400 or greater (4% per year), thus demonstrating that diabetes is not universally a CHD risk equivalent but is associated with significant heterogeneity in risk (Figure 7)24. More than one-third of our cohort with diabetes had CAC scores of 0 and CHD risk was lower than many persons without DM or MetS; thus, this raises question regarding whether DM is in fact a CHD risk equivalent. The ACCF/AHA statement has noted with a class IIa level of evidence B recommendation that measurement of CAC is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk, as well as at low to intermediate risk based on 6-10% (class IIb), but not in those at low risk. However, those with diabetes aged >40 are also appropriate for CAC measurement (Class IIa level of evidence B)2. We have also demonstrated progression of CAC has also recently been demonstrated to be independently associated with future CHD event risk25; however, guidelines thus far have not endorsed repeat CAC scanning for stratification of risk or treatment26.

We showed the identification of CAC has also been shown to be related in an observational study to be related to the subject’s greater likelihood of practicing preventive behaviors, such as starting aspirin or cholesterol medicine, losing weight, and seeing a doctor, with the extent of calcification also shown to be related to the likelihood of certain behaviors27. More recently, in the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research (EISNER) prospective randomized trial, where over 2,000 asymptomatic subjects were randomized 2:1 to calcium scanning or not to scanning, those who received scanning showed no increase in their Framingham risk score 4 years later, compared to an increase in the risk score seen among those not received scanning28. Also, in a very recent report, the greater the lifestyle score (number of healthy lifestyle behaviors), the less the incidence or progression of CAC seen from serial CAC scanning in MESA29.

Some have argued that CAC testing might increase the utilization of other testing, but this has not been proven. In fact, the Eisner Study of subjects randomized to CAC testing or no testing showed no significant difference in the incidence of downstream testing over 4 years of follow-up28. In addition, the radiation dose from CAC scanning has been shown to be similar to that of a mammogram or a long distance air flight.

Further, CAC scanning can help identify those most likely to have a positive nuclear myocardial perfusion test; the likelihood of such a test being positive is quite low unless CAC scores exceed 40030. Among those with diabetes or metabolic syndrome, a threshold CAC score of 100 is seen to identify those with an increased likelihood of a positive nuclear study31. Thus, CAC scanning may serve as a useful gatekeeper for identifying those most likely to benefit from nuclear myocardial perfusion testing.
There has also been interest in whether CAC testing can help identify those who may or may not benefit from statin therapy. In the Jupiter eligible population from MESA (e.g., LDL-C<130, hs CRP>2, and no DM) it was shown that only 25% of subjects had a CAC>100 and when the Jupiter relative risk reduction was applied to the CHD event rates observed in this group, it would take only 24 persons treated with a statin to prevent one event; however, in the 27% with CAC 1-100, the number need to treat (NNT) was 94 and in the remainder with CAC=0, the NNT was 5432. Thus, CAC testing was able to identify persons with significant subclinical atherosclerosis who had a higher baseline CHD risk and who would be most likely to benefit from statin therapy.

When all the noninvasive screening modalities are examined together in MESA, a recent report shows CAC to be by far the strongest predictor and is associated with the greatest incremental value improvement by the C-statistic over Framingham Risk Score33.

CT Angiography and Non-Calcified Plaque. CT Angiography has paved the way for identification of non-calcified and vulnerable plaque characteristics (Figure 8) with quantification that compares well to that of intravascular ultrasound34; certain feature such as positive remodeling, spoty calcification, and low attenuation non-calcified plaque.<30 HU have been shown to have a high predictive value for culprit plaques associated with acute coronary syndrome36 and in a subsequent study involving follow-up of 1059 patients who underwent CT angiography, those with at least two of these features were significantly more likely to develop future acute coronary syndrome36. However, due to the radiation and contrast enhancement required, the ACCF/AHA recommendations still do not indicate it for CVD risk assessment in asymptomatic adults2. Nevertheless, the number of diseased vessels from CT angiography has been shown to be a strong predictor of prognosis37, although information provided by CT angiography does not appear to add further information to prediction of CHD events over that of CAC38.

References


